Mood and substance use disorders commonly co-occur, yet there is little evidence-based research to guide the pharmacologic management of these comorbid disorders. The authors review the existing empirical findings including current clinical pharmacotherapy practices for treating co-occurring mood and substance use disorders and call into question current clinical practices. The specific mood disorders reviewed are bipolar and major depressive disorders (either one co-occurring with a substance use disorder). The authors also highlight knowledge gaps that may serve as a basis for future research. Findings from the relatively small amount of available data indicate that pharmacotherapy for managing mood symptoms might be effective in patients with substance dependence, although results have not been consistent across all studies. In most studies, medications for managing mood symptoms did not appear to have an impact on the substance use disorder. Research has only begun to address optimal pharmacologic management of co-occurring disorders. In addition, current clinical treatment for drug dependence often exclude new pharmacotherapies approved by the French Haute Autorité de Santé for treating certain types of addiction. With new data becoming available, it appears that we need to revisit current practice in the pharmacological management of co-occurring mood and substance use disorders.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S0013-7006(14)70124-1 | DOI Listing |
Bronchopulmonary dysplasia (BPD) is a chronic lung disease, with its own clinical, radiological and histopathological characteristics, which mainly affects premature newborns, resulting from a combination of factors that include immaturity, inflammation and lung injury, in addition to therapy with mechanical ventilation and exposure to high concentrations of oxygen. However, even with advances in care for critically ill newborns, BPD continues to be a challenge for the care team and family members. This has been identified as one of the most important causes of morbidity and mortality due to prematurity, and can have significant impacts on the quality of life of the affected patients.
View Article and Find Full Text PDFUltrason Sonochem
January 2025
Université Paris Cité, Institut de Physique du Globe de Paris, CNRS, F-75005 Paris, France. Electronic address:
Perfluorooctanesulfonic acid (PFOS) is one of the most investigated Per- and polyfluoroalkyl substances (PFAS) for being the strongest compound to eliminate and having adverse health concerns. In this work, we have conducted the sonochemical treatment of PFOS simulated water under high (500 kHz) and low (22 kHz) frequencies while monitoring the operational parameters via an integrated sonochemical system. The integrated advanced sonochemical system includes software to monitor treatment power, solution temperature and frequency while allowing distinctive control of the reaction conditions.
View Article and Find Full Text PDFEcotoxicol Environ Saf
January 2025
Univ. Bordeaux, CNRS, Bordeaux INP, EPOC, UMR 5805, Pessac F-33600, France. Electronic address:
Plastic products contain complex mixtures of chemical compounds that are incorporated into polymers to improve material properties. Besides the intentional chemical additives, other compounds including residual monomers and non-intentionnaly added substances (NIAS) as well as sorbed pollutants are usually also present in aged plastic. Since most of these substances are only loosely bound to the polymer via non-covalently interactions, i.
View Article and Find Full Text PDFJ Expo Sci Environ Epidemiol
January 2025
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.
Background: Exposure to per and poly-fluoroalkyl substances (PFAS) is suggested to interfere with the central nervous system that may affect mental health. Studies on the relationships between exposure to PFAS mixtures and anxiety in humans are rare. This study aimed to evaluate the associations between single and combined exposure to PFAS and anxiety among adults.
View Article and Find Full Text PDFSevere mental illness (SMI) encompasses depression, bipolar disorder, and schizophrenia which affect the daily quality of life. While it has a significant impact on their social life, it is also supposedly linked with various comorbidities, of which, cardiovascular disease (CVD) is the most frequently reported. Various biological, behavioral, and genetic mechanisms are thought to play a role: hypothalamic-pituitary-adrenal axis, autonomic nervous system dysregulation, inflammation, and psychotropic medications.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!